University of Alabama at Birmingham Researchers Provide New Insights into Biopharmaceuticals (A lactobacilli-based inhaled live biotherapeutic product attenuates pulmonary neutrophilic inflammation).

A recent study conducted by researchers at the University of Alabama at Birmingham explores the use of biopharmaceuticals in treating chronic lung diseases such as bronchopulmonary dysplasia (BPD) and chronic obstructive pulmonary disease (COPD). The researchers found that a lactobacilli-based inhaled live biotherapeutic product (LBP) showed promise in improving lung structure and function, reducing inflammation, and mitigating neutrophil influx in mouse models of these diseases. The study suggests that inhaled LBPs could potentially target common pathways of disease progression in various chronic lung diseases. Further research is needed to explore the potential of LBPs as a therapeutic option. [Extracted from the article]